Human CD56bright and CD56dim natural killer cell subsets respond differentially to direct stimulation with Mycobacterium bovis bacillus Calmette-Guérin

Scandinavian Journal of Immunology

Volumn 62, Issue 6, 2005, Pages 498-506

  Batoni, G ^a   Esin, S ^a   Favilli, F ^a   Pardini, Manuela ^a,b   Bottai, D ^a   Maisetta, G ^a   Florio, W ^a   Campa, M ^a  

^a UNIVERSITY OF PISA   (Italy)

^b ISTITUTO SUPERIORE DI SANITÀ   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE; BROXURIDINE; CD56 ANTIGEN; GAMMA INTERFERON; GRANZYME A; LIVE VACCINE; NYLON; PERFORIN; GRANZYME; GZMA PROTEIN, HUMAN; MEMBRANE PROTEIN; PORE FORMING CYTOTOXIC PROTEIN; SERINE PROTEINASE;

APOPTOSIS; ARTICLE; BACTERIAL VIRULENCE; CELL ADHESION; CELL STRAIN K 562; CORRELATION ANALYSIS; CYTOKINE PRODUCTION; CYTOTOXICITY; EXOCYTOSIS; HUMAN; HUMAN CELL; IN VITRO STUDY; INCUBATION TIME; LYMPHOCYTE ACTIVATION; MYCOBACTERIUM BOVIS; NATURAL KILLER CELL; NONHUMAN; NORMAL HUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN CONTENT; PURIFICATION; STAINING; TARGET CELL; WOOL; ALLELE; BIOSYNTHESIS; CELL CULTURE; CELL PROLIFERATION; COMPARATIVE STUDY; GENETICS; IMMUNOLOGY; LYMPHOCYTE SUBPOPULATION; METABOLISM; MICROBIOLOGY; PHYSIOLOGY;

ALLELES; ANTIGENS, CD56; BCG VACCINE; CELL PROLIFERATION; CELLS, CULTURED; CYTOTOXICITY, IMMUNOLOGIC; GRANZYMES; HUMANS; INTERFERON TYPE II; KILLER CELLS, NATURAL; LYMPHOCYTE ACTIVATION; LYMPHOCYTE SUBSETS; MEMBRANE GLYCOPROTEINS; MYCOBACTERIUM BOVIS; PORE FORMING CYTOTOXIC PROTEINS; SERINE ENDOPEPTIDASES;

EID: 28944445570     PISSN: 03009475     EISSN: 13653083     Source Type: Journal    
DOI: 10.1111/j.1365-3083.2005.01692.x     Document Type: Article

References (28)

1. Trinchieri G. Biology of natural killer cells. Adv Immunol 1989;47:187-376.
2. Cooper MA, Fehniger TA, Caligiuri MA. The biology of human natural killer-cell subsets. Trends Immunol 2001;22:633-40.
3. Bancroft GJ. The role of natural killer cells in innate resistance to infection. Curr Opin Immunol 1993;5:503-10.
4. bright subset. Blood 2001;97:3146-51.
5. Nagler A, Lanier LL, Cwirla S, Phillips JH. Comparative studies of human FcRIII-positive and negative natural killer cells. J Immunol 1989;143:3183-91.
6. bright natural killer cells are present in human lymph nodes and are activated by T cell-derived IL-2: a potential new link between adaptive and innate immunity. Blood 2003;101:3052-7.
7. Ferlazzo G, Thomas D, Lin SL et al. The abundant NK cells in human secondary lymphoid tissues require activation to express killer Ig-like receptors and become cytolytic. J Immunol 2004;172:1455-62.
8. neg natural killer cells is selectively responsible for both cell proliferation and interferon-γ production upon interaction with dendritic cells. Eur J Immunol 2004;34:1715-22.
9. dim NK cells. Eur J Immunol 2001;31:3121-6.
10. Chalifour A, Jeannin P, Gauchat JF et al. Direct bacterial protein PAMP recognition by human NK cells involves TLRs and triggers α-defensin production. Blood 2004;104:1778-83.
11. Esin S, Batoni G, Pardini M et al. Functional characterization of human natural killer cells responding to Mycobacterium bovis bacillus Calmette-Guérin. Immunology 2004;112:143-52.
12. Esin S, Batoni G, Källenius G et al. Proliferation of distinct human T cell subsets in response to live killed and soluble bacterial extracts of Mycobacterium tuberculosis and M. avium. Clin Exp Immunol 1996;104:419-25.
13. + individuals upon stimulation with Mycobacterium tuberculosis. Infect Immun 1999;67:3800-9.
14. Waterhouse NJ, Trapani JA. CTL: caspases terminate life but that's not the whole story. Tissue Antigens 2002;59:175-83.
15. bright NK cells in treatment-naive HIV-1-seropositive individual. J Clin Immunol 2002;22:176-83.
16. +bright cell activation and apoptosis in hepatitis C virus infection. Clin Exp Immunol 2004;137:408-16.
17. Cooper MA, Fehniger TA, Ponnappan A, Mehta V, Wewers MD, Caligiuri MA. Interleukin-1β costimulates interferon-γ production by human natural killer cells. Eur J Immunol 2001;31:792-801.
18. Carson WE, Ross ME, Baiocchi RA et al. Endogenous production of interleukin 15 by activated human monocytes is critical for optimal production of interferon-γ by natural killer cells in vitro. J Clin Invest 1995;96:2578-82.
19. Fehniger TA, Carson WE, Caligiuri MA. Costimulation of human natural killer cells is required for interferon gamma production. Transplant Proc 1999;31:1476-8.
20. Batoni G, Esin S, Pardini M et al. Identification of distinct lymphocyte subsets responding to subcellular fractions of Mycobacterium bovis bacille Calmette-Guérin. Clin Exp Immunol 2000;119:270-9.
21. Karakousis PC, Bishai WR, Dorman SE. Mycobacterium tuberculosis cell envelope lipids and the host immune response. Cell Microbiol 2004;6:105-16.
22. Blanchard DK, McMillen S, Hoffman SL, Djeu JY. Mycobacterial induction of activated killer cells: possible role of tyrosine kinase activity in interleukin-2 receptor alpha expression. Infect Immun 1992;60:2843-9.
23. Haller D, Blum S, Bode C, Hammes WP, Schiffrin EJ. Activation of human blood mononuclear cells by non pathogenic bacteria in vitro: evidence of NK cells as primary targets. Infect Immun 2000;68:752-9.
24. Klimpel GR, Nielsen DW, Asuncion M, Klimpel KD. Natural killer cell activation and interferon production by peripheral blood lymphocytes after exposure to bacteria. Infect Immun 1998;56:1436-41.
25. Nylén S, Maasho K, Söderström K, Ilg T, Akuffo H. Live Leishmania promastigotes can directly activate primary human natural killer cells to produce interferon-gamma. Clin Exp Immunol 2003;131:457-67.
26. Tarkkanen J, Saksela E. Potentiation of human natural killer cell cytotoxicity by Salmonella bacteria is an interferon- and interleukin-2- independent process that utilizes CD2 and CD18 structures in the effector phase. Infect Immun 1991;59:2767-73.
27. + natural killer cell subsets and its induction by interleukin-2. Immunol Invest 1995;24:499-507.
28. Caligiuri MA, Murray C, Robertson MJ et al. Selective modulation of human natural killer cells in vivo after prolonged infusion of low dose recombinant interleukin-2. J Clin Invest 1993;91:123-32.